pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro Citations (23)

Originally described in: Tracking genome engineering outcome at individual DNA breakpoints.
Certo MT, Ryu BY, Annis JE, Garibov M, Jarjour J, Rawlings DJ, Scharenberg AM Nat Methods. 2011 Jul 10;8(8):671-6. doi: 10.1038/nmeth.1648. PubMed Journal

---

Articles Citing pCVL Traffic Light Reporter 1.1 (Sce target) Ef1a Puro

Articles
Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. Certo MT, Gwiazda KS, Kuhar R, Sather B, Curinga G, Mandt T, Brault M, Lambert AR, Baxter SK, Jacoby K, Ryu BY, Kiem HP, Gouble A, Paques F, Rawlings DJ, Scharenberg AM. Nat Methods. 2012 Oct;9(10):973-5. doi: 10.1038/nmeth.2177. Epub 2012 Sep 2. PubMed Associated Plasmids pExodus pExodus CMV.Trex2 pExodus CMV.Artemis
Design and analysis of site-specific single-strand nicking endonucleases for gene correction. Metzger MJ, Certo MT. Methods Mol Biol. 2014;1114:237-44. doi: 10.1007/978-1-62703-761-7_15. PubMed
Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A. Nature. 2015 Feb 12;518(7538):254-7. doi: 10.1038/nature14157. Epub 2015 Feb 2. PubMed Associated Plasmids pX330(puro) Rosa26-H3F3B pcDNA 3.1(Hygro) myc-hPolQ-Flag
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Rasmussen RD, Gajjar MK, Jensen KE, Hamerlik P. Mol Oncol. 2016 Jan 8. pii: S1574-7891(16)00002-8. doi: 10.1016/j.molonc.2015.12.014. PubMed
Probing the impact of chromatin conformation on genome editing tools. Chen X, Rinsma M, Janssen JM, Liu J, Maggio I, Goncalves MA. Nucleic Acids Res. 2016 Jun 8. pii: gkw524. PubMed Associated Plasmids AW01_pU.CAG.eSpCas9(1.1).rBGpA
Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Chroma K, Mistrik M, Moudry P, Gursky J, Liptay M, Strauss R, Skrott Z, Vrtel R, Bartkova J, Kramara J, Bartek J. Oncogene. 2016 Nov 14. doi: 10.1038/onc.2016.392. PubMed
Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Lu J, Zhao C, Zhao Y, Zhang J, Zhang Y, Chen L, Han Q, Ying Y, Peng S, Ai R, Wang Y. Nucleic Acids Res. 2018 Mar 16;46(5):e25. doi: 10.1093/nar/gkx1222. PubMed Associated Plasmids ScFv-2ERT2-V EF1a-Cas9-2XNES-2ERT2-GCN4-SV40-Zeo ScFv-2ERT2-VPH
Multiple Chemical Inducible Tal Effectors for Genome Editing and Transcription Activation. Zhao C, Zhang Y, Zhao Y, Ying Y, Ai R, Zhang J, Wang Y. ACS Chem Biol. 2018 Mar 16;13(3):609-617. doi: 10.1021/acschembio.7b00606. Epub 2018 Jan 8. PubMed Associated Plasmids 2ERT2-AAVS1 TALEN-L EF1a-3NLS-Klf4 TALE-GCN4 EF1a-3NLS-NGN2TALE-GCN4 EF1a-3NLS-Sox2TALE-GCN4
Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing. Mir A, Alterman JF, Hassler MR, Debacker AJ, Hudgens E, Echeverria D, Brodsky MH, Khvorova A, Watts JK, Sontheimer EJ. Nat Commun. 2018 Jul 6;9(1):2641. doi: 10.1038/s41467-018-05073-z. PubMed
The shieldin complex mediates 53BP1-dependent DNA repair. Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Alvarez-Quilon A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18. PubMed Associated Plasmids pcDNA5-FRT/TO-FLAG-SHLD1 pCW-eGFP-SHLD1 pcDNA5-FRT/TO-FLAG-SHLD2 pGLUE-SHLD2 pCW-eGFP-SHLD2 More ...
HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control. Zhao C, Zhao Y, Zhang J, Lu J, Chen L, Zhang Y, Ying Y, Xu J, Wei S, Wang Y. Mol Ther Nucleic Acids. 2018 Dec 7;13:208-219. doi: 10.1016/j.omtn.2018.08.022. Epub 2018 Sep 1. PubMed Associated Plasmids EF1a-Cas9-2XNES-2ERT2
RIF1 promotes replication fork protection and efficient restart to maintain genome stability. Mukherjee C, Tripathi V, Manolika EM, Heijink AM, Ricci G, Merzouk S, de Boer HR, Demmers J, van Vugt MATM, Ray Chaudhuri A. Nat Commun. 2019 Jul 23;10(1):3287. doi: 10.1038/s41467-019-11246-1. PubMed
Control of homologous recombination by the HROB-MCM8-MCM9 pathway. Hustedt N, Saito Y, Zimmermann M, Alvarez-Quilon A, Setiaputra D, Adam S, McEwan A, Yuan JY, Olivieri M, Zhao Y, Kanemaki MT, Jurisicova A, Durocher D. Genes Dev. 2019 Oct 1;33(19-20):1397-1415. doi: 10.1101/gad.329508.119. Epub 2019 Aug 29. PubMed Associated Plasmids pcDNA5-FRT-T0-Flag-HROB pcDNA5-FRT-T0-eGFP-HROB
WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors. Burdova K, Storchova R, Palek M, Macurek L. Cells. 2019 Oct 15;8(10). pii: cells8101258. doi: 10.3390/cells8101258. PubMed
Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity. Ohba S, Johannessen TA, Chatla K, Yang X, Pieper RO, Mukherjee J. Cell Rep. 2020 Apr 14;31(2):107518. doi: 10.1016/j.celrep.2020.03.082. PubMed
CAM-Delam: an in vivo approach to visualize and quantify the delamination and invasion capacity of human cancer cells. Palaniappan TK, Slekiene L, Jonasson AK, Gilthorpe J, Gunhaga L. Sci Rep. 2020 Jun 26;10(1):10472. doi: 10.1038/s41598-020-67492-7. PubMed
The dystonia gene THAP1 controls DNA double-strand break repair choice. Shinoda K, Zong D, Callen E, Wu W, Dumitrache LC, Belinky F, Chari R, Wong N, Ishikawa M, Stanlie A, Multhaupt-Buell T, Sharma N, Ozelius L, Ehrlich M, McKinnon PJ, Nussenzweig A. Mol Cell. 2021 Jun 17;81(12):2611-2624.e10. doi: 10.1016/j.molcel.2021.03.034. Epub 2021 Apr 14. PubMed
A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells. Mukherjee J, Pandita A, Kamalakar C, Johannessen TC, Ohba S, Tang Y, Dalle-Ore CL, Bjerkvig R, Pieper RO. Sci Transl Med. 2021 May 5;13(592). pii: 13/592/eabc7211. doi: 10.1126/scitranslmed.abc7211. PubMed
A Validated Functional Analysis of Partner and Localizer of BRCA2 Missense Variants for Use in Clinical Variant Interpretation. Brnich SE, Arteaga EC, Wang Y, Tan X, Berg JS. J Mol Diagn. 2021 Jul;23(7):847-864. doi: 10.1016/j.jmoldx.2021.04.010. Epub 2021 May 6. PubMed
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. J Clin Invest. 2021 Jun 1;131(11). pii: e146256. doi: 10.1172/JCI146256. PubMed
5'-Modifications improve potency and efficacy of DNA donors for precision genome editing. Ghanta KS, Chen Z, Mir A, Dokshin GA, Krishnamurthy PM, Yoon Y, Gallant J, Xu P, Zhang XO, Ozturk AR, Shin M, Idrizi F, Liu P, Gneid H, Edraki A, Lawson ND, Rivera-Perez JA, Sontheimer EJ, Watts JK, Mello CC. Elife. 2021 Oct 19;10. pii: 72216. doi: 10.7554/eLife.72216. PubMed
A non-canonical, interferon-independent signaling activity of cGAMP triggers DNA damage response signaling. Banerjee D, Langberg K, Abbas S, Odermatt E, Yerramothu P, Volaric M, Reidenbach MA, Krentz KJ, Rubinstein CD, Brautigan DL, Abbas T, Gelfand BD, Ambati J, Kerur N. Nat Commun. 2021 Oct 27;12(1):6207. doi: 10.1038/s41467-021-26240-9. PubMed
Functional characterization of C21ORF2 association with the NEK1 kinase mutated in human in diseases. Gregorczyk M, Pastore G, Munoz I, Carroll T, Streubel J, Munro M, Lis P, Lange S, Lamoliatte F, Macartney T, Toth R, Brown F, Hastie J, Pereira G, Durocher D, Rouse J. Life Sci Alliance. 2023 May 15;6(7):e202201740. doi: 10.26508/lsa.202201740. Print 2023 Jul. PubMed

If you have published an article using this material, please email us at to have your article added to this page.